Abstract
We conducted a prospective trial of sequential administration of oral ethinyl estradiol (EE) with medroxyprogesterone acetate (MPA) in postmenopausal women with estrogen receptorpositive breast carcinoma that had not been treated with additive hormonal therapy. A 14-day treatment cycle consisted of 1.0 mg/day EE on days 1 and 2, 400 mg/day MPA on days 3 through 12, and no treatment on days 13 and 14. Seven (44%) of the 16 evaluable patients had partial responses, but no complete responses were observed. The median duration of response was 7.6 months. Fifty-three percent of the patients experienced therapy-related complications including two cases of thromboembolism. Estrogen priming before progestin therapy as used in this study cannot be recommended for routine use because the response rate does not seem to be better than that of monohormonal therapy in the face of a high incidence of complications.
| Original language | English |
|---|---|
| Pages (from-to) | 87-94 |
| Number of pages | 8 |
| Journal | Breast Disease |
| Volume | 3 |
| Issue number | 2 |
| State | Published - Jul 1 1990 |
Fingerprint
Keywords
- breast carcinoma
- ethinyl estradiol
- medroxyprogesterone acetate
ASJC Scopus subject areas
- Surgery
Cite this
Estrogen priming before progestin therapy in advanced breast cancer. / Hung, Shaun S J; East, Dawn; Vogel, Charles; Wang, Grace; Hilsenbeck, Susan G.
In: Breast Disease, Vol. 3, No. 2, 01.07.1990, p. 87-94.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Estrogen priming before progestin therapy in advanced breast cancer
AU - Hung, Shaun S J
AU - East, Dawn
AU - Vogel, Charles
AU - Wang, Grace
AU - Hilsenbeck, Susan G.
PY - 1990/7/1
Y1 - 1990/7/1
N2 - We conducted a prospective trial of sequential administration of oral ethinyl estradiol (EE) with medroxyprogesterone acetate (MPA) in postmenopausal women with estrogen receptorpositive breast carcinoma that had not been treated with additive hormonal therapy. A 14-day treatment cycle consisted of 1.0 mg/day EE on days 1 and 2, 400 mg/day MPA on days 3 through 12, and no treatment on days 13 and 14. Seven (44%) of the 16 evaluable patients had partial responses, but no complete responses were observed. The median duration of response was 7.6 months. Fifty-three percent of the patients experienced therapy-related complications including two cases of thromboembolism. Estrogen priming before progestin therapy as used in this study cannot be recommended for routine use because the response rate does not seem to be better than that of monohormonal therapy in the face of a high incidence of complications.
AB - We conducted a prospective trial of sequential administration of oral ethinyl estradiol (EE) with medroxyprogesterone acetate (MPA) in postmenopausal women with estrogen receptorpositive breast carcinoma that had not been treated with additive hormonal therapy. A 14-day treatment cycle consisted of 1.0 mg/day EE on days 1 and 2, 400 mg/day MPA on days 3 through 12, and no treatment on days 13 and 14. Seven (44%) of the 16 evaluable patients had partial responses, but no complete responses were observed. The median duration of response was 7.6 months. Fifty-three percent of the patients experienced therapy-related complications including two cases of thromboembolism. Estrogen priming before progestin therapy as used in this study cannot be recommended for routine use because the response rate does not seem to be better than that of monohormonal therapy in the face of a high incidence of complications.
KW - breast carcinoma
KW - ethinyl estradiol
KW - medroxyprogesterone acetate
UR - http://www.scopus.com/inward/record.url?scp=0025164621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025164621&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0025164621
VL - 3
SP - 87
EP - 94
JO - Breast Disease
JF - Breast Disease
SN - 0888-6008
IS - 2
ER -